This phenotype is found in a subset of BCs, more commonly in BC with equivocal HER2 protein expression and low-grade HER2 gene amplification, and is reported to be associated with poor clinical outcome in patients with HER2-positive primary BC. The gene discussed is ERBB2; the disease is breast cancer.